| Home | ||
| About NCCTG | ||
| About Clinical Trials | ||
| NCCTG Trial Listings | ||
| Treating Locations | ||
NCCTG News
| ||
| Patient Advocacy | ||
| Biospecimen Access | ||
| Links | ||
| System | ||
| Institutional Members Only |
Researchers Study Alternative to Venlafaxine for Hot Flashes - 02/28/2006
Hot flashes are a major problem for many women as they approach menopause. Estrogen-based therapy had been the standard therapy for many years, resulting in an 80 to 90 percent reduction in hot flashes. However, concerns about a link between estrogen and progesterone combined therapy and an increased risk of breast cancer, heart disease and/or cognitive dysfunction were reported in articles about the “Women’s Health Initiative” published in JAMA in 2002 and 2004, and have led to a search for alternate therapies.
- 04/25/2005
Results from two large randomized clinical trials for patients with HER-2 positive early-stage invasive breast cancer show that patients who received trastuzumab (Herceptin®) in combination with chemotherapy had a significant decrease in risk for breast cancer recurrence compared with patients who received the same chemotherapy without trastuzumab.
Abnormal Protein Indicates Poorer Prognosis for Patients with Rapidly Growing, Malignant Brain Tumors - 06/03/2004
ROCHESTER, Minn. — Patients who have brain tumors that contain an abnormal protein, called EGFRvIII, respond poorly to standard treatments and should be offered the choice of experimental therapies sooner, according to a study led by Mayo Clinic and the North Central Cancer Treatment Group (NCCTG).
Jan Buckner, M.D., will report the findings at the 40th annual meeting of the American Society of Clinical Oncology (ASCO), June 7, in New Orleans. Dr. Buckner is a neuro-oncologist at Mayo Clinic in Rochester, and chair of NCCTG, a network of more than 400 community-based cancer treatment clinics in the United States and Canada that work with Mayo Clinic to conduct clinical studies for advancing cancer treatment.
© Copyright 2008, NCCTG